{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-091613","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.233323+00:00","generated_at":"2026-05-18T13:17:03.150582+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results","bullets":["Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.","Oral presentation of long-term PATHFNDR-1 open-label extension data for paltusotine in acromegaly, showing durable biochemical and symptom control.","Phase 2 open-label trial results for atumelnant in congenital adrenal hyperplasia featured as oral presentation; data on adrenal volume and androgen reductions.","Early-stage pipeline data on CRN12755, a TSHR antagonist for Graves' hyperthyroidism and orbitopathy, also to be presented.","PALSONIFY conditionally approved as trade name by FDA; atumelnant Phase 2 interim results show rapid reductions in androstenedione and 17-hydroxyprogesterone."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-091613","json":"https://secwatch.observer/filing/0000950170-25-091613.json","markdown":"https://secwatch.observer/filing/0000950170-25-091613.md","text":"https://secwatch.observer/filing/0000950170-25-091613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/0000950170-25-091613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/crnx-20250630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:17:03.150582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}